Trial review
Tirzepatide and Type 2 Diabetes Prevention
Progression to type 2 diabetes
SURMOUNT-1, three-year prediabetes analysis was a prespecified analysis of a phase 3 randomised double-blind placebo-controlled trial funded by Eli Lilly and Company. Three years of tirzepatide produced substantial sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than placebo. That figure belongs to the population, dose, comparator and 176 weeks of treatment followed by a 17-week off-treatment period shown below, and describes a group average under trial conditions rather than a prediction for any individual.
| Design | Prespecified analysis of a phase 3 randomised double-blind placebo-controlled trial |
|---|---|
| Population | The 1,032 SURMOUNT-1 participants who had both obesity and prediabetes |
| Sample size | 1,032 of 2,539 |
| Intervention | Tirzepatide once weekly |
| Comparator | Placebo |
| Duration | 176 weeks of treatment followed by a 17-week off-treatment period |
| Primary endpoint | Progression to type 2 diabetes, plus three-year weight change and safety |
| Main result | Three years of tirzepatide produced substantial sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than placebo |
Show this figure as a table
| Step | Stage | What happens |
|---|---|---|
| 1 | Who was eligible | The 1,032 SURMOUNT-1 participants who had both obesity and prediabetes |
| 2 | What they received | Tirzepatide once weekly |
| 3 | What it was compared against | Placebo |
| 4 | For how long | 176 weeks of treatment followed by a 17-week off-treatment period |
| 5 | What was measured first | Progression to type 2 diabetes, plus three-year weight change and safety |
| 6 | What the group average was | Three years of tirzepatide produced substantial sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than placebo |
| 7 | What it does not tell you | A group average is not a prediction for any individual reader. |
Show this figure as a table
| Item | Weight change | Evidence |
|---|---|---|
| Intervention group | not captured | |
| Comparator group | not captured |
| Question | Position |
|---|---|
| Average effect in the studied population | Reported once captured |
| Your individual outcome | Not predicted by any trial |
| Effect of a compounded preparation | Not studied here |
| Effect at doses outside the protocol | Not studied here |
| Effect after stopping | Only if the trial included a withdrawal phase |
| Long-term safety beyond the trial | Outside the observation window |
Who was studied
- Inclusion and exclusion criteria in plain language. Say who was not studied — that is usually the more useful half.
What was given, and what it was compared against
- Dose, titration schedule, comparator, and whether the comparator was placebo or an active drug.
Results
- Primary endpoint first, with absolute numbers alongside percentages. Secondary endpoints labelled as secondary.
Adverse events and discontinuations
- Never omitted for length. Report discontinuation rates alongside efficacy.
Limitations
- Funding, blinding, dropout handling, generalisability, duration.
How this should and should not be read
- Explicitly address the misreadings this trial commonly attracts.
How it compares with other trials
- Only where designs are comparable. Say so when they are not.
- Retrieve the registry record and the peer-reviewed publication. Record NCT, DOI and PMID.
- Do not summarise from a manufacturer press release, a conference abstract described as a result, or a news article.
- Where only topline or preprint data exists, label it as such everywhere it appears, including the direct answer.
- Medical review is mandatory on this page before publication.
Questions readers actually ask
Does this mean I would lose that much weight?
No. Trials report group averages under controlled conditions with specific eligibility criteria. Individual results vary widely, and the trial population may not resemble you.
Do these results apply to compounded tirzepatide?
Not automatically. Trials studied the approved product at studied doses. A compounded preparation at a different concentration, formulation or route has not been through those trials.
Related on this site
- Research hubResearch
- SURMOUNT-1 Tirzepatide Trial ExplainedResearch
- SURMOUNT-3 Tirzepatide Trial ExplainedResearch
- SURMOUNT-4: Weight Maintenance and Tirzepatide WithdrawalResearch
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Tirzepatide and Diabetes Prevention Over 176 WeeksJournal
- Tirzepatide and Chronic Kidney DiseaseResearch
- Tirzepatide and Cardiovascular OutcomesResearch
GLP-1 Tirzepatide Review. “Tirzepatide and Type 2 Diabetes Prevention.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/research/tirzepatide-diabetes-prevention/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.